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P U B L I S H E D B Y E L S E V I E R I N C .LettersFavorable Impact on LDL
Particle Size in Response
to Treatment With
Pioglitazone is Associated
With Less Progression of
Coronary Atherosclerosis in
PatientsWith Type 2 DiabetesA preponderance of small, dense low-density lipo-
protein (LDL) particles may promote the accelerated
plaque progression seen on intravascular ultrasound
(IVUS) imaging in patients with diabetes, even when
LDL cholesterol appears to be well controlled (1).
The PERISCOPE (Pioglitazone Effect on Regression
of Intravascular Sonographic Coronary Obstruction
Prospective Evaluation; NCT00225277) trial demon-
strated that the peroxisome proliferator-activated
receptor–gamma agonist, pioglitazone, halted athe-
roma progression in patients with diabetes, with evi-
dence that lowering the triglyceride/high-density
lipoprotein (HDL) cholesterol ratio was independently
associated with this beneﬁt (2). We investigated the
relationship between changes in LDL particle mea-
sures and disease progression because LDL cholesterol
levels did not change.
PERISCOPE compared the effects of pioglitazone and
glimepiride on plaque progression using serial IVUS im-
aging in 543 patients with type 2 diabetes and angio-
graphic coronary artery disease (2). Lipid particle size and
concentration were determined by nuclear magnetic
resonance spectroscopy (LipoScience, Raleigh, North
Carolina) on plasma samples (3). Analysis of covariance
compared the percent changes of lipoprotein parameters
and the percent of atheroma volume (PAV), adjusting for
baseline measures. Multivariable linear regression anal-
ysis determined independent predictors of disease pro-
gression, adjusting for clinical characteristics and
biochemical parameters.
Clinical characteristics and concomitantmedication
use were similar in the treatment groups, except for
less smoking in the pioglitazone group (10.1% vs.
19.3%; p ¼ 0.01). Pioglitazone-treated patientsdemonstrated greater increases in HDL cholesterol
(15.1  1.2% vs. 2.8  1.2%; p < 0.001), mean LDL
particle size (3.8  0.21% vs. 0.74  0.20%; p < 0.001),
and large LDL concentration (66.5  4.3% vs. 16.6 
4.2%; p< 0.001), and greater decreases in triglycerides
(–16.9  2.6% vs. 1.0  2.6%; p < 0.001), total LDL
particles (–15.9  1.7% vs. –1.3  1.6%; p < 0.001), and
small LDL concentration (–39.0  3.7% vs. –3.4  3.6%;
p < 0.001).
Changes in PAV were associated with increases in
small (r ¼ 0.19; p < 0.001) and total LDL (r ¼ 0.12; p ¼
0.02) particle concentrations, and with decreases in
large LDL particle concentration (r ¼ –0.14; p ¼ 0.008)
and mean LDL particle size (r ¼ –0.21; p < 0.001).
After adjusting for treatment group, plaque progres-
sion was associated with decreasing mean LDL par-
ticle size (p ¼ 0.003) and increasing small LDL particle
concentration (p ¼ 0.07) (Table 1). A signiﬁcant
interaction between on-treatment mean LDL particle
size and LDL cholesterol was observed (p ¼ 0.04),
with less PAV progression associated with changes in
mean LDL particle size more than the median in the
setting of LDL <70 mg/dl (–0.89  0.48% vs. 1.01 
0.44%; p ¼ 0.004) and LDL cholesterol 70 to 100 mg/
dl (–0.21  0.30% vs. 0.56  0.32%; p ¼ 0.08), but not
when LDL cholesterol was >100 mg/dl (p ¼ 0.83).
Multivariable analysis, adjusting for baseline PAV and
treatment group, revealed that the percent change in
mean LDL particle size (p ¼ 0.004), large LDL con-
centration (p ¼ 0.02), and small LDL concentration
(p ¼ 0.02) were signiﬁcantly associated with changes
in PAV.
Our analysis revealed that pioglitazone exerted a
favorable impact on LDL particle measures; it
increased particle size and decreased particle con-
centration, and was associated with less plaque pro-
gression. These results supported observations that
small LDL particles were associated with angio-
graphic progression and cardiovascular events (4),
suggesting that LDL cholesterol might not completely
reﬂect ongoing cardiovascular risk. Monitoring LDL
particle–based measures might provide incremental
risk prediction in patients with low LDL cholesterol
levels, and help identify those who might beneﬁt
from more intensive lipid modiﬁcation. The obser-
vation that particle-based measures were less reliable
in the presence of higher LDL cholesterol levels was
TABLE 1 Change in Lipid and Lipoproteins and Atheroma Progression
Tertile 1 Tertile 2 Tertile 3 p Value
p Value Adjusting
for Treatment Group
LDL-C 0.44  0.24 0.14  0.24 0.32  0.24 0.71 0.69
HDL-C 0.64  0.24 0.43  0.24 –0.22  0.24 0.01 0.10
Triglyceride –0.03  0.24 0.35  0.24 0.59  0.24 0.07 0.19
Total LDL particles 0.04  0.24 0.35  0.24 0.39  0.24 0.32 0.97
Mean LDL
particle size
0.82  0.24 0.51  0.24 –0.54  0.24 <0.001 0.003
Large LDL 0.65  0.24 0.16  0.24 –0.04  0.24 0.047 0.25
Small LDL –0.35  0.24 0.44  0.24 0.70  0.24 0.002 0.07
Values are mean  SD. Changes in percent atheroma volume were stratiﬁed according to tertiles of percentage change in lipid and lipoprotein parameters.
C ¼ cholesterol; HDL ¼ high-density lipoprotein; LDL ¼ low-density lipoprotein.
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329not surprising because of the established cardiovas-
cular risk in this setting.
Insulin resistance, hyperglycemia, hypertrigly-
ceridemia, and systemic inﬂammation promote small
LDL particle accumulation in diabetes. Even after
controlling for the favorable effects of pioglitazone
on these factors, increasing LDL particle size was
associated with less disease progression. This has
important implications for the development of
diabetic therapies and the increased use of lipid-
lowering agents to more effectively lower cardiovas-
cular risk.Preethi Mani, MD
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Interpreting
Blood Pressure in
Younger Adults
The remarkable paper from the Chicago Heart Asso-
ciation Detection Project in Industry Study (1) studied
cardiovascular mortality (3,119 deaths) over 31 years
in 27,081 initially well persons, according to initial
categorizations of systolic and diastolic hypertension,
isolated diastolic hypertension, isolated systolic
hypertension (ISH), high-normal blood pressure (BP),
and optimal-normal BP. The results validate recent
concerns that results of treating elderly persons
(>60 years) cannot be applied universally to younger
persons, as in the 18- to 49-year age group described
here (2).
The Central Illustration in Yano et al. (1) shows,
for male subjects, little or no deviation in outcome
up to 20 years compared with high-normal BP or
optimal-normal BP, but considerable deviation from
the other 2 hypertensive groups. We have argued
that ISH in young male subjects may be “spurious”
